An important example of blood-based LBx clinical utility is the assessment of epidermal growth factor receptor (EGFR) mutations in circulating tumor DNA to guide the use of EGFR tyrosine kinase inhibitors in patients with advanced-stage non-small-cell lung carcinoma5,6. The gene discussed is EGFR; the disease is neoplasm.